Carbetocin is a long-acting synthetic agonist analogue of human oxytocin, with antihemorrhagic and uterotonic activities. Upon administration, carbetocin targets, binds to and activates peripheral oxytocin receptors that are present on the smooth musculature of the uterus. This causes uterus contractions and prevents excessive bleeding after childbirth, particularly following Cesarean section, and may be used to decrease blood loss during hysteroscopic myomectomy.
CAT No: R1961
CAS No: 37025-55-1
Chemical Name: (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisRegistration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | Carbetocin;37025-55-1;Pabal;Carbetocino;Carbetocinum;carbetocine;Carbetocina;CHEBI:59204;Carbetocinum [INN-Latin];Carbetocino [INN-Spanish];Duratocin (TN);LV-101;deamino-2-O-methyltyrosine-1-carbaoxytocin;88TWF8015Y;CARBETOCIN [MI];1-butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin;CARBETOCIN [INN];1-Butyric acid-2-(3-(p-methoxyphenyl)-L-alanine)oxytocin;CARBETOCIN [USAN];CARBETOCIN [MART.];CARBETOCIN [WHO-DD];Carbetocin [USAN:INN:BAN];UNII-88TWF8015Y;FE 992097;FE-992097;DTXSID90897527;EINECS 253-312-6;1-Carbaoxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-;Carbetocinum (INN-Latin);Carbetocino (INN-Spanish);CARBETOCIN (MART.);(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide;1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin;1-Carboxytocin, 1-butanoic acid-2-(O-methyl-L-tyrosine)-;dcomot;(2S)-2-{[(2S)-1-{[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide;1-{[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-L-prolyl-L-leucylglycinamide;GLYCINAMIDE, N-(4-MERCAPTO-1-OXOBUTYL)-O-METHYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-, CYCLIC (1->5)-THIOETHER;O-METHYL-N-(4-SULFANYLBUTANOYL)-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-GLYCINAMIDE CYCLIC (1->5)-THIOETHER;Carbetocin?;C45H69N11O12S;(2S)-2-(((2S)-1-(((3R,6S,9S,12S,15S)-12-((2S)-butan-2-yl)-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-((4-methoxyphenyl)methyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl)carbonyl)pyrrolidin-2-yl)formamido)-N-(carbamoylmethyl)-4-methylpentanamide;(2S)-N-((2S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-((2S)-butan-2-yl)-15-((4-methoxyphenyl)methyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl)pyrrolidine-2-carboxamide;1-(((3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-((2S)-butan-2-yl)-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl)carbonyl)-L-prolyl-L-leucylglycinamide;MFCD01076600;Duratocin long acting;Carbetocin (Standard);1-deamino-1-monocarba-2-(Tyr(OMe))-oxytocin;SCHEMBL39224;Carbetocin (USAN/INN/BAN);oxytocin, 1-desamino-1-monocarba-(Tyr(OMe))(2)-;CHEMBL3301668;GTPL11169;H01BB03;NSTRIRCPWQHTIA-DTRKZRJBSA-N;DTXCID901326882;oxytocin, 1-desamino-1-monocarba-(tyrosine(O-methyl))(2)-;WHO 5014;BDBM50044677;HY-17573R;AKOS015994647;DB01282;FB19694;HS-2007;NCGC00485451-02;HY-17573;NS00056256;D07229;Carbetocin 100 microg/mL in Acetonitrile:Methanol;Q5037853;1-Deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin;BRD-K56107812-001-01-7;1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin;Deamino-2-O-methyltyrosine-1-carbaoxytocin;Depotocin;Carbetocin;253-312-6; |
M.F/Formula | C45H69N11O12S |
M.W/Mr. | 988.2 |
Sequence | [But1-Cys6] But-Tyr(Me)-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 |
Appearance | Solid powder |
Activity | Agonist |
Biological Activity | Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS. |
Target | Oxytocin Receptor |
InChI | InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1 |
InChI Key | NSTRIRCPWQHTIA-DTRKZRJBSA-N |
Canonical SMILES | CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N |
Isomeric SMILES | CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com